Stay updated on Nab-Paclitaxel/Gemcitabine±Olaratumab in Metastatic Pancreatic Ca Clinical Trial
Sign up to get notified when there's something new on the Nab-Paclitaxel/Gemcitabine±Olaratumab in Metastatic Pancreatic Ca Clinical Trial page.

Latest updates to the Nab-Paclitaxel/Gemcitabine±Olaratumab in Metastatic Pancreatic Ca Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal regarding a clinical study for metastatic pancreatic cancer, including details about the study's purpose, inclusion and exclusion criteria, and contact information for the study director. The revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference11%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to Nab-Paclitaxel/Gemcitabine±Olaratumab in Metastatic Pancreatic Ca Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Paclitaxel/Gemcitabine±Olaratumab in Metastatic Pancreatic Ca Clinical Trial page.